|
Market Closed -
Australian S.E.
21:49:22 2026-10-15 EDT
|
5-day change | 1st Jan Change | ||
| 0.0120 AUD | +9.09% |
|
+9.09% | -20.00% |
| 10-12 | Acrux Limited - Shareholder/Analyst Call | |
| 08-26 | Acrux Limited Reports Earnings Results for the Full Year Ended June 30, 2026 | CI |
| Market Cap | 7.08M 4.92M 4.38M 4.06M 3.69M 6.96M 467M 48.76M 19.12M 244M 18.48M 18.08M 777M | P/E 2025 |
-0.95x | P/E 2026 | -8.4x |
|---|---|---|---|---|---|
| Enterprise Value | 7.89M 5.49M 4.88M 4.52M 4.11M 7.76M 521M 54.36M 21.31M 272M 20.6M 20.16M 867M | EV / Sales 2025 |
2.07x | EV / Sales 2026 | 1.08x |
| Free-Float |
89.9% | Yield 2025 * |
-
| Yield 2026 | - |
Australian S.E.AUD
| Markets | Quality | ||
|---|---|---|---|
Australian S.E.
| ACR | Delayed | |
OTC Markets
| ARUXF | Delayed | |
Deutsche Boerse AG
| FJY | Delayed |
Last Transcript: Acrux Limited
| 22-05-22 | Acrux : Application for quotation of securities - ACR | PU |
| 22-04-13 | Acrux : Application for quotation of securities - ACR | PU |
| 22-03-15 | Acrux : Application for quotation of securities - ACR | PU |
| 22-02-24 | Acrux : Updated Board Charter | PU |
| 22-02-24 | Acrux : Application for quotation of securities - ACR | PU |
| 1 day | +9.09% | ||
| 1 week | +9.09% | ||
| Current month | +33.33% | ||
| 1 month | +20.00% | ||
| 6 months | +9.09% | ||
| Current year | -20.00% |
| 1 week | 0.01 | 0.01 | |
| 1 month | 0.01 | 0.01 | |
| Current year | 0.01 | 0.02 | |
| 1 year | 0.01 | 0.02 | |
| 3 years | 0.01 | 0.1 | |
| 5 years | 0.01 | 0.13 | |
| 10 years | 0.01 | 0.36 |
| Manager | Title | Age | Since |
|---|---|---|---|
John Warmbrunn
CEO | Chief Executive Officer | - | 2025-05-31 |
Joanna Johnson
DFI | Director of Finance/CFO | - | 2021-06-20 |
Jolanta Airey
CTO | Chief Tech/Sci/R&D Officer | - | 2026-08-23 |
| Director | Title | Age | Since |
|---|---|---|---|
Ross Dobinson
CHM | Chairman | 74 | 2005-12-31 |
Timothy Oldham
BRD | Director/Board Member | - | 2013-09-30 |
Geoff Brooke
BRD | Director/Board Member | 70 | 2016-05-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +9.09% | +9.09% | -7.69% | -72.09% | 4.92M | ||
| +0.43% | +6.59% | +56.57% | +106.64% | 1,120B | ||
| +0.90% | -2.25% | +32.26% | +63.73% | 616B | ||
| +0.71% | +3.24% | +24.33% | +91.33% | 504B | ||
| -0.13% | +5.98% | +33.66% | +50.18% | 367B | ||
| +0.52% | +0.24% | +72.13% | +40.11% | 360B | ||
| -0.95% | +4.70% | +19.65% | +42.71% | 288B | ||
| -1.98% | +3.73% | -0.89% | +10.43% | 258B | ||
| -0.35% | +4.25% | +44.74% | +52.06% | 234B | ||
| -0.75% | +3.32% | +27.18% | +94.07% | 194B | ||
| Average | +0.75% | +4.16% | +30.19% | +47.92% | 394.09B | |
| Weighted average by Cap. | +0.13% | +3.83% | +39.34% | +71.82% |
| 2025 | 2026 | |
|---|---|---|
| Net sales | 4.49M 3.12M 2.78M 2.57M 2.34M 4.42M 296M 30.93M 12.13M 155M 11.72M 11.47M 493M | 6.58M 4.58M 4.07M 3.77M 3.43M 6.48M 435M 45.35M 17.78M 227M 17.19M 16.82M 723M |
| Net income | -5.94M -4.14M -3.68M -3.41M -3.1M -5.85M -393M -40.97M -16.06M -205M -15.52M -15.19M -653M | -604K -420K -374K -346K -315K -594K -39.89M -4.16M -1.63M -20.81M -1.58M -1.54M -66.35M |
| Net Debt | 2.77M 1.93M 1.71M 1.59M 1.45M 2.73M 183M 19.1M 7.49M 95.52M 7.24M 7.08M 305M | 813K 566K 503K 466K 424K 800K 53.69M 5.6M 2.2M 28.02M 2.12M 2.08M 89.31M |
Employees
43
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-10-16 | A$0.0120 | +9.09% | 124,836 |
| 26-10-15 | A$0.0110 | -8.33% | 757,667 |
| 26-10-14 | A$0.0120 | +9.09% | 374,390 |
| 26-10-13 | A$0.0110 | -15.38% | 2,074,380 |
| 26-10-12 | A$0.0130 | +18.18% | 6,472,358 |
Annual profits - Rate of surprise
- Stock Market
- Stocks
- ACR Stock
Select your edition
All financial news and data tailored to specific country editions

















